Alternative HPV vaccination schedules in Latin America
In 2008, the first HPV vaccination program in Latin America started in Panama, targeting girls aged 10-11 years with a 3-dose vaccine schedule, an initiative that was to be followed by other Latin American countries after local feasibility and population acceptability evaluations were completed. A 3...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Instituto Nacional de Salud Pública
2018-12-01
|
Series: | Salud Pública de México |
Subjects: | |
Online Access: | http://www.saludpublica.mx/index.php/spm/article/view/9810 |
id |
doaj-a20f18f944ca42d0bce4e678bad537b7 |
---|---|
record_format |
Article |
spelling |
doaj-a20f18f944ca42d0bce4e678bad537b72020-11-24T21:09:31ZengInstituto Nacional de Salud PúblicaSalud Pública de México0036-36341606-79162018-12-01606, nov-dic69370210.21149/981016607Alternative HPV vaccination schedules in Latin AmericaClaudia Robles0María de la Luz Hernández1Maribel Almonte21.- International Agency for Research on Cancer (IARC/WHO), Lyon, France 2.-Institut Catala d'Oncologia, Barcelona, SpainInternational Agency for Research on Cancer (IARC/WHO), Lyon, FranceInternational Agency for Research on Cancer (IARC/WHO), Lyon, FranceIn 2008, the first HPV vaccination program in Latin America started in Panama, targeting girls aged 10-11 years with a 3-dose vaccine schedule, an initiative that was to be followed by other Latin American countries after local feasibility and population acceptability evaluations were completed. A 3-dose vaccine regimen over six months was originally chosen for HPV vaccines, copying the Hepatitis B vaccine schedule (0, 1-2, 6 months). Alternative vaccine schedules have been proposed afterwards based on: i) noninferior immunogenicity or immune response levels compared to those at which clinical efficacy has been proven (i.e., those observed in a 3-dose HPV vaccine schedule in women aged 15-26), and, ii) proven efficacy in clinical trials and/or effectiveness among women who were provided less than three doses due to a lack of adherence to a 3-dose vaccine schedule. In 2014, based on the available evidence and the potential increase in coverage by expansion of vaccination target groups, particularly in low and middle income countries (LMIC), the World Health Organization recommended a 2-dose schedule with at least a 6-month interval between doses for females up to 15 years of age and a 3-dose schedule for older women. More recently, it has been suggested that 1-dose HPV vaccination schemes may provide enough protection against HPV infection and may speed up the introduction of HPV vaccination in LMIC, where most needed.http://www.saludpublica.mx/index.php/spm/article/view/9810VPH vaccinationvaccination schedulesnumber of vaccine doses |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Claudia Robles María de la Luz Hernández Maribel Almonte |
spellingShingle |
Claudia Robles María de la Luz Hernández Maribel Almonte Alternative HPV vaccination schedules in Latin America Salud Pública de México VPH vaccination vaccination schedules number of vaccine doses |
author_facet |
Claudia Robles María de la Luz Hernández Maribel Almonte |
author_sort |
Claudia Robles |
title |
Alternative HPV vaccination schedules in Latin America |
title_short |
Alternative HPV vaccination schedules in Latin America |
title_full |
Alternative HPV vaccination schedules in Latin America |
title_fullStr |
Alternative HPV vaccination schedules in Latin America |
title_full_unstemmed |
Alternative HPV vaccination schedules in Latin America |
title_sort |
alternative hpv vaccination schedules in latin america |
publisher |
Instituto Nacional de Salud Pública |
series |
Salud Pública de México |
issn |
0036-3634 1606-7916 |
publishDate |
2018-12-01 |
description |
In 2008, the first HPV vaccination program in Latin America started in Panama, targeting girls aged 10-11 years with a 3-dose vaccine schedule, an initiative that was to be followed by other Latin American countries after local feasibility and population acceptability evaluations were completed. A 3-dose vaccine regimen over six months was originally chosen for HPV vaccines, copying the Hepatitis B vaccine schedule (0, 1-2, 6 months). Alternative vaccine schedules have been proposed afterwards based on: i) noninferior immunogenicity or immune response levels compared to those at which clinical efficacy has been proven (i.e., those observed in a 3-dose HPV vaccine schedule in women aged 15-26), and, ii) proven efficacy in clinical trials and/or effectiveness among women who were provided less than three doses due to a lack of adherence to a 3-dose vaccine schedule. In 2014, based on the available evidence and the potential increase in coverage by expansion of vaccination target groups, particularly in low and middle income countries (LMIC), the World Health Organization recommended a 2-dose schedule with at least a 6-month interval between doses for females up to 15 years of age and a 3-dose schedule for older women. More recently, it has been suggested that 1-dose HPV vaccination schemes may provide enough protection against HPV infection and may speed up the introduction of HPV vaccination in LMIC, where most needed. |
topic |
VPH vaccination vaccination schedules number of vaccine doses |
url |
http://www.saludpublica.mx/index.php/spm/article/view/9810 |
work_keys_str_mv |
AT claudiarobles alternativehpvvaccinationschedulesinlatinamerica AT mariadelaluzhernandez alternativehpvvaccinationschedulesinlatinamerica AT maribelalmonte alternativehpvvaccinationschedulesinlatinamerica |
_version_ |
1716758147701407744 |